Search

Displaying results 3291 - 3300 of 10000 in total
  1. Target

    Calnexin

    go.drugbank.com/bio_entities/BE0001011
    TargetHumans

    Associated with partial T-cell antigen receptor complexes that escape the ER of immature thymocytes, it may function as a signaling complex regulating thymocyte maturation.

    Synonyms: Major histocompatibility complex class I antigen-binding protein p88
  2. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    It is used in the management of severe pain.

    Synonyms: (−)-N-cyclobutylmethyl-3,14-dihydroxymorphinan
  3. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  4. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Iodoquinol is not currently available in any FDA-approved products. … Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown.

  5. Drug

    Zimelidine

    go.drugbank.com/drugs/DB04832
    ApprovedWithdrawn

    Additionally, zimelidine was charged to cause an increase in suicidal ideation and/or attempts among depressive patients. … worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin

  6. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  7. Drug

    Ferrous cysteine glycinate

    go.drugbank.com/drugs/DB11197
    Approved

    Mixtures: Enl
  8. Drug

    Acepromazine

    go.drugbank.com/drugs/DB01614
    InvestigationalVet approved

    Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic.

  9. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in … [L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376]

    Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-
  10. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    It is not approved for use in any country, but is currently in clinical trials in the United States. … Azimilide is an investigational class III anti-arrhythmic drug that blocks fast and slow components of the delayed rectifier cardiac potassium channels.